Literature DB >> 28513693

Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)].

Benjamin W J Harper1, Emanuele Petruzzella, Roman Sirota, Fernanda Fabiola Faccioli, Janice R Aldrich-Wright, Valentina Gandin, Dan Gibson.   

Abstract

This report describes the synthesis, characterization and biological activity of a series of platinum(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)] (Pt56MeSS) with non-bioactive, lipophilic and bioactive axial ligands. In an attempt to explore the anticancer activity potential of the Pt(iv) derivatives, 2D and 3D cytotoxic screening and a preliminary in vivo study were performed. The average IC50 values of the platinum(iv) derivatives ranged from 1.26 to 5.39 μM, compared with 1.24 μM for Pt56MeSS, suggesting that the axial ligands have a relatively minor effect on the potency of the compounds. Preliminary in vivo studies indicate that the platinum(iv) derivatives of Pt56MeSS are active in vivo and can reduce the tumor to a similar extent to cisplatin.

Entities:  

Year:  2017        PMID: 28513693     DOI: 10.1039/c7dt01054k

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  3 in total

1.  Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity.

Authors:  Aleen Khoury; Jennette A Sakoff; Jayne Gilbert; Kieran F Scott; Shawan Karan; Christopher P Gordon; Janice R Aldrich-Wright
Journal:  Pharmaceutics       Date:  2022-04-03       Impact factor: 6.525

2.  Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.

Authors:  Sandeep Rana; Smit Kour; Yogesh A Sonawane; Caroline M Robb; Jacob I Contreras; Smitha Kizhake; Muhammad Zahid; Adam R Karpf; Amarnath Natarajan
Journal:  Chem Biol Drug Des       Date:  2020-04-22       Impact factor: 2.817

Review 3.  Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands.

Authors:  Xuejiao Li; Yahong Liu; Hongqi Tian
Journal:  Bioinorg Chem Appl       Date:  2018-10-01       Impact factor: 7.778

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.